Search | Médecins Sans Frontières Access Campaign

2705 results found

Letter |

21 September 2023

Ukraine: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Ukraine sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson Ukraine

Letter |

21 September 2023

Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Moldova sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Intellectual property and trade tuberculosis bedaquiline Johnson & Johnson Republic of Moldova

Letter |

21 September 2023

Azerbaijan: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Azerbaijan sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson Azerbaijan

GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Press release |

19 September 2023

TB test price reduction by Cepheid and Danaher is an important step in the right direction

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert Johnson & Johnson

Bottle of bedaquiline, Zhytomyr Regional TB Dispensary, Ukraine. In 2018, MSF started providing treatment for drug-resistant TB to people in Zhytomyr, Ukraine.

Photo credit: Oksana Parafeniuk

Blog |

15 September 2023

The long and winding road to ensure affordable access to a key TB drug

With the United Nations High-Level meeting just over the horizon, the TB community is ready to amplify the voices of people affected by TB around the world at this global forum, and demand the global attention and resources needed to beat this devastating yet curable disease.

Technical brief |

15 September 2023

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

The ongoing PPR negotiations at WHO offer an opportunity to resolve the decades-long tension between IP and access

Tags Pandemic preparednessIntellectual property and trade coronavirus TRIPS WTO

Press release |

12 September 2023

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

MSF calls on J&J and Cepheid/Danaher to commit to improving access to key TB drug and test by UNHLM 22 September

Tags DiagnosticsTuberculosis

Newsletter |

12 September 2023

Join the Time for $5 campaign to save millions of lives

Today we hit the road running with our campaign, ‘Time for $5’, calling on the US company Cepheid, and its parent corporation Danaher, to drop the price of a lifesaving test, GeneXpert, to save millions of people’s lives around the world.

Research article |

11 September 2023

The Lancet Child & Adolescent Health: Reversing the neglect of children and adolescents affected by tuberculosis

MSF and co-authors call for commitments from countries at the UNHLM on TB to address gaps in TB care for children and adolescents.

Tags Tuberculosis tuberculosis

A clinician gathering antiretroviral medications for a patient at Maram Dispensary in Ndhiwa sub county, Homa Bay County, Kenya, 2021

Press release |

17 August 2023

MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA

MSF urges ViiV to withdraw problematic purchasing conditions hindering access to HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Mr and Ms Kimboi, both of whom are living with HIV, picking up their medicines at the MSF Chakpikarong clinic, Thailand, 2019

Letter |

17 August 2023

Open letter to ViiV to improve access to HIV prevention drug CAB-LA

MSF letter to ViiV asking the company to withdraw problematic purchasing conditions for HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Video |

17 August 2023

Testimonies for access to HIV prevention drug CAB-LA

CAB-LA is a game-changing HIV prevention medicine, but access to it is currently a challenge.

Tags HIV/AIDS HIV/AIDS cabotegravir

Moussa, type I diabetes patient, in MSF project in Arsal, Lebanon.

Feature story |

07 August 2023

Moussa's story: Access to insulin pens in humanitarian settings

How insulin pens simplify lives for children living with Type 1 diabetes.

Tags Diabetes Diabetes Insulin

Letter |

31 July 2023

Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply

Open letter by CSOs to US pharma J&J seeking clarification on the deal for supply of generic versions of TB bedaquiline

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline Johnson & Johnson

MSF medical staff administers measles vaccinations to children in Ndjala village, Drodro Ituri province, Democratic Republic of Congo, May 2023

Press release |

18 July 2023

Gavi must do more as WHO/UNICEF estimates show slow childhood vaccination recovery

MSF again called on Gavi to broaden catch-up vaccine coverage for children by waiving co-financing requirements of countries with fragile health systems

Tags Vaccines Gavi, the Vaccine Alliance

Press release |

17 July 2023

MSF calls for commitment from pharma corporation J&J to not enforce extended patents on lifesaving TB drug as main patent expires in India, opening door to affordable generics

MSF calls on Johnson & Johnson not to enforce its secondary patents on TB drug bedaquiline

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson

Technical brief |

17 July 2023

MSF Position Paper: Ensuring Timely and Equitable Access to Medical Products in Global Public Health Emergencies

Principles and actions for equitable access to medical products

Tags Pandemic preparednessIntellectual property and tradeResearch and development TRIPS

Deepak, who lives with DR-TB, was treated with the TB medicine bedaquiline. Mumbai, India, 2022.

Press release |

13 July 2023

TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries

MSF calls on J&J not to enforce secondary patents on TB drug bedaquiline, to improve global access to this lifesaving medicine

Tags Intellectual property and tradeTuberculosis tuberculosis

After discovering she is HIV positive, Gisela suffered from anxiety, depression and panic attacks. Buenaventura, Colombia, 2016.

Press release |

13 July 2023

Colombia to challenge AIDS drug patents

MSF signed onto a letter supporting Colombia’s action to possibly issue a compulsory license to improve access to HIV drug dolutegravir

Tags HIV/AIDSIntellectual property and trade Colombia

Letter |

13 July 2023

CSO letter supporting Resolution 881/23 by Colombia on issuing a compulsory license for HIV drug dolutegravir

MSF co-signed a CSO letter to Colombia welcoming a resolution on issuing a compulsory license for HIV drug dolutegravir

Tags HIV/AIDSIntellectual property and trade HIV/AIDS Colombia

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Ukraine: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Azerbaijan: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

TB test price reduction by Cepheid and Danaher is an important step in the right direction

The long and winding road to ensure affordable access to a key TB drug

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

Join the Time for $5 campaign to save millions of lives

The Lancet Child & Adolescent Health: Reversing the neglect of children and adolescents affected by tuberculosis

MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA

Open letter to ViiV to improve access to HIV prevention drug CAB-LA

Testimonies for access to HIV prevention drug CAB-LA

Moussa's story: Access to insulin pens in humanitarian settings

Open letter: Requesting clarification from J&J on the recent deal for generic bedaquiline supply

Gavi must do more as WHO/UNICEF estimates show slow childhood vaccination recovery

MSF calls for commitment from pharma corporation J&J to not enforce extended patents on lifesaving TB drug as main patent expires in India, opening door to affordable generics

MSF Position Paper: Ensuring Timely and Equitable Access to Medical Products in Global Public Health Emergencies

TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries

Colombia to challenge AIDS drug patents

CSO letter supporting Resolution 881/23 by Colombia on issuing a compulsory license for HIV drug dolutegravir